Drug profile

The FDA adverse-event record for Lysozyme & Lactoferrin

54 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Lysozyme & Lactoferrin. See the species affected, top reactions, and outcomes below.

54
adverse-event reports
14.8%
death-coded share
Dog
most-reported species
11
Lethargy (see also Central nervous system depression in 'Neurological') - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
54
Total Reports
8
Deaths Reported
14.8%
Death Rate

Active Ingredients

Lysozyme & Lactoferrin

Administration Routes

UnknownAuricular (Otic)Topical

Species Affected

Dog 52
Cat 2

Most Affected Breeds

Retriever - Labrador 10
Spaniel (unspecified) 4
Terrier - Yorkshire 4
Shih Tzu 2
Domestic Shorthair 2
Beagle 2
Shepherd Dog - German 2
Chihuahua 2
Pug 2
Bichon Frise 2

Most Reported Reactions

Lethargy (see also Central nervous system depression in 'Neurological') 11
Vomiting 7
Behavioural disorder NOS 6
Anorexia 6
Other abnormal test result NOS 5
Panting 5
Death by euthanasia 5
Abnormal ultrasound finding 4
Diarrhoea 4
Facial swelling (see also 'Skin') 4
Anaphylactoid reaction 4
INEFFECTIVE, LOSS OF EFFECT 4

Outcome Breakdown

Ongoing
27 (50.0%)
Recovered/Normal
15 (27.8%)
Euthanized
5 (9.3%)
Outcome Unknown
4 (7.4%)
Died
3 (5.6%)

Lysozyme & Lactoferrin Adverse Event Insights

54 reports name Lysozyme & Lactoferrin; 8 recorded a death outcome (14.8% of reported events, not a population-level mortality rate). Active ingredient: Lysozyme & Lactoferrin. Administration routes: Unknown, Auricular (Otic), Topical.

By species: Dog (52 reports), Cat (2 reports). By breed: Retriever - Labrador (10), Spaniel (unspecified) (4), Terrier - Yorkshire (4).

Leading clinical signs: Lethargy (see also Central nervous system depression in 'Neurological') (11), Vomiting (7), Behavioural disorder NOS (6), Anorexia (6). Outcome, 54 coded reports: Ongoing leads at 50.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.